Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Shares Issued (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Shares Issued for 5 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 16.11% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2025, up 88.36% year-over-year, with the annual reading at $5.7 million for FY2025, 88.36% up from the prior year.
  • Shares Issued hit $1.8 million in Q4 2025 for ARS Pharmaceuticals, up from $479000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $2.9 million in Q2 2023 to a low of -$1.0 million in Q4 2021.
  • Historically, Shares Issued has averaged $907500.0 across 5 years, with a median of $702500.0 in 2024.
  • Biggest five-year swings in Shares Issued: skyrocketed 894.43% in 2023 and later tumbled 80.9% in 2024.
  • Year by year, Shares Issued stood at -$1.0 million in 2021, then surged by 127.85% to $283000.0 in 2022, then surged by 537.81% to $1.8 million in 2023, then decreased by 15.07% to $1.5 million in 2024, then grew by 16.11% to $1.8 million in 2025.
  • Business Quant data shows Shares Issued for SPRY at $1.8 million in Q4 2025, $479000.0 in Q3 2025, and $2.7 million in Q2 2025.